Prognostic factors and risk-stratification model of recurrent or metastatic head and neck squamous cell carcinoma treated with cetuximab containing regimen
In recent years, the addition of cetuximab to chemotherapy has improved treatment outcomes for patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). In this study, we present the real-world survival data of R/M HNSCC patients who received cetuximab-containing regimens...
Saved in:
| Published in | BMC cancer Vol. 24; no. 1; pp. 1227 - 11 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central Ltd
05.10.2024
BioMed Central BMC |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | In recent years, the addition of cetuximab to chemotherapy has improved treatment outcomes for patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). In this study, we present the real-world survival data of R/M HNSCC patients who received cetuximab-containing regimens from thirteen medical centers in Taiwan, as well as a three-level risk stratification model for this patient population.
This study enrolled R/M HNSCC patients from thirteen medical centers in Taiwan who received cetuximab-containing regimens from January 1, 2017 to June 6, 2022. The cases were divided into a training cohort and a validation cohort based on the start of treatment. Overall survival (OS) was evaluated in both cohorts and exploratory analysis was performed to identify associated adverse clinical and laboratory factors. The results of the exploratory analysis were used to construct a three-level risk stratification prediction model for OS.
A total of 1434 patients with R/M HNSCC were enrolled in this study and received cetuximab-containing regimens. The overall population had a median OS of 8.57 months (95% CI: 8.07 - 9.08). Multivariate analysis of the training cohort identified poor ECOG performance status, heavy alcohol consumption, and prior adjuvant CCRT or lack of prior RT as adverse prognostic factors. Comparison of laboratory data between patients with OS≦6 and OS > 6 also revealed unfavorable factors, including increased white blood cell count, decreased hemoglobin level, increased platelet count, increased absolute neutrophil count, decreased absolute lymphocyte count, and increased neutrophil-to-lymphocyte ratio. Using forward prediction, a three-level risk stratification prediction model was constructed using the variables of ECOG performance status, alcohol consumption, skin metastasis, modality of radiation therapy, hemoglobin level, and neutrophil-to-lymphocyte ratio. The median OS in the low-risk, intermediate-risk, and high-risk groups were 12.02 months (95% CI 10.44-13.61), 7.5 months (95% CI 7.33-8.17), and 4.01 months (95% CI 3.94-4.08), respectively, with a log-rank test p-value < 0.001.
This study presents a three-level risk stratification model with strong prediction ability for OS in R/M HNSCC patients who received cetuximab-containing regimens. The results are based on real-world data and may provide valuable information for clinicians in treatment planning and future drug development. |
|---|---|
| AbstractList | In recent years, the addition of cetuximab to chemotherapy has improved treatment outcomes for patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). In this study, we present the real-world survival data of R/M HNSCC patients who received cetuximab-containing regimens from thirteen medical centers in Taiwan, as well as a three-level risk stratification model for this patient population. This study enrolled R/M HNSCC patients from thirteen medical centers in Taiwan who received cetuximab-containing regimens from January 1, 2017 to June 6, 2022. The cases were divided into a training cohort and a validation cohort based on the start of treatment. Overall survival (OS) was evaluated in both cohorts and exploratory analysis was performed to identify associated adverse clinical and laboratory factors. The results of the exploratory analysis were used to construct a three-level risk stratification prediction model for OS. A total of 1434 patients with R/M HNSCC were enrolled in this study and received cetuximab-containing regimens. The overall population had a median OS of 8.57 months (95% CI: 8.07 - 9.08). Multivariate analysis of the training cohort identified poor ECOG performance status, heavy alcohol consumption, and prior adjuvant CCRT or lack of prior RT as adverse prognostic factors. Comparison of laboratory data between patients with OSâ¦6 and OS > 6 also revealed unfavorable factors, including increased white blood cell count, decreased hemoglobin level, increased platelet count, increased absolute neutrophil count, decreased absolute lymphocyte count, and increased neutrophil-to-lymphocyte ratio. Using forward prediction, a three-level risk stratification prediction model was constructed using the variables of ECOG performance status, alcohol consumption, skin metastasis, modality of radiation therapy, hemoglobin level, and neutrophil-to-lymphocyte ratio. The median OS in the low-risk, intermediate-risk, and high-risk groups were 12.02 months (95% CI 10.44-13.61), 7.5 months (95% CI 7.33-8.17), and 4.01 months (95% CI 3.94-4.08), respectively, with a log-rank test p-value < 0.001. This study presents a three-level risk stratification model with strong prediction ability for OS in R/M HNSCC patients who received cetuximab-containing regimens. The results are based on real-world data and may provide valuable information for clinicians in treatment planning and future drug development. Abstract Background In recent years, the addition of cetuximab to chemotherapy has improved treatment outcomes for patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). In this study, we present the real-world survival data of R/M HNSCC patients who received cetuximab-containing regimens from thirteen medical centers in Taiwan, as well as a three-level risk stratification model for this patient population. Methods This study enrolled R/M HNSCC patients from thirteen medical centers in Taiwan who received cetuximab-containing regimens from January 1, 2017 to June 6, 2022. The cases were divided into a training cohort and a validation cohort based on the start of treatment. Overall survival (OS) was evaluated in both cohorts and exploratory analysis was performed to identify associated adverse clinical and laboratory factors. The results of the exploratory analysis were used to construct a three-level risk stratification prediction model for OS. Results A total of 1434 patients with R/M HNSCC were enrolled in this study and received cetuximab-containing regimens. The overall population had a median OS of 8.57 months (95% CI: 8.07 – 9.08). Multivariate analysis of the training cohort identified poor ECOG performance status, heavy alcohol consumption, and prior adjuvant CCRT or lack of prior RT as adverse prognostic factors. Comparison of laboratory data between patients with OS≦6 and OS > 6 also revealed unfavorable factors, including increased white blood cell count, decreased hemoglobin level, increased platelet count, increased absolute neutrophil count, decreased absolute lymphocyte count, and increased neutrophil-to-lymphocyte ratio. Using forward prediction, a three-level risk stratification prediction model was constructed using the variables of ECOG performance status, alcohol consumption, skin metastasis, modality of radiation therapy, hemoglobin level, and neutrophil-to-lymphocyte ratio. The median OS in the low-risk, intermediate-risk, and high-risk groups were 12.02 months (95% CI 10.44–13.61), 7.5 months (95% CI 7.33–8.17), and 4.01 months (95% CI 3.94–4.08), respectively, with a log-rank test p-value < 0.001. Conclusion This study presents a three-level risk stratification model with strong prediction ability for OS in R/M HNSCC patients who received cetuximab-containing regimens. The results are based on real-world data and may provide valuable information for clinicians in treatment planning and future drug development. Background In recent years, the addition of cetuximab to chemotherapy has improved treatment outcomes for patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). In this study, we present the real-world survival data of R/M HNSCC patients who received cetuximab-containing regimens from thirteen medical centers in Taiwan, as well as a three-level risk stratification model for this patient population. Methods This study enrolled R/M HNSCC patients from thirteen medical centers in Taiwan who received cetuximab-containing regimens from January 1, 2017 to June 6, 2022. The cases were divided into a training cohort and a validation cohort based on the start of treatment. Overall survival (OS) was evaluated in both cohorts and exploratory analysis was performed to identify associated adverse clinical and laboratory factors. The results of the exploratory analysis were used to construct a three-level risk stratification prediction model for OS. Results A total of 1434 patients with R/M HNSCC were enrolled in this study and received cetuximab-containing regimens. The overall population had a median OS of 8.57 months (95% CI: 8.07 - 9.08). Multivariate analysis of the training cohort identified poor ECOG performance status, heavy alcohol consumption, and prior adjuvant CCRT or lack of prior RT as adverse prognostic factors. Comparison of laboratory data between patients with OSâ¦6 and OS > 6 also revealed unfavorable factors, including increased white blood cell count, decreased hemoglobin level, increased platelet count, increased absolute neutrophil count, decreased absolute lymphocyte count, and increased neutrophil-to-lymphocyte ratio. Using forward prediction, a three-level risk stratification prediction model was constructed using the variables of ECOG performance status, alcohol consumption, skin metastasis, modality of radiation therapy, hemoglobin level, and neutrophil-to-lymphocyte ratio. The median OS in the low-risk, intermediate-risk, and high-risk groups were 12.02 months (95% CI 10.44-13.61), 7.5 months (95% CI 7.33-8.17), and 4.01 months (95% CI 3.94-4.08), respectively, with a log-rank test p-value < 0.001. Conclusion This study presents a three-level risk stratification model with strong prediction ability for OS in R/M HNSCC patients who received cetuximab-containing regimens. The results are based on real-world data and may provide valuable information for clinicians in treatment planning and future drug development. Keywords: Cetuximab, Head and neck squamous cell carcinoma, Prognostic factor, Risk-stratification model In recent years, the addition of cetuximab to chemotherapy has improved treatment outcomes for patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). In this study, we present the real-world survival data of R/M HNSCC patients who received cetuximab-containing regimens from thirteen medical centers in Taiwan, as well as a three-level risk stratification model for this patient population. This study enrolled R/M HNSCC patients from thirteen medical centers in Taiwan who received cetuximab-containing regimens from January 1, 2017 to June 6, 2022. The cases were divided into a training cohort and a validation cohort based on the start of treatment. Overall survival (OS) was evaluated in both cohorts and exploratory analysis was performed to identify associated adverse clinical and laboratory factors. The results of the exploratory analysis were used to construct a three-level risk stratification prediction model for OS. A total of 1434 patients with R/M HNSCC were enrolled in this study and received cetuximab-containing regimens. The overall population had a median OS of 8.57 months (95% CI: 8.07 - 9.08). Multivariate analysis of the training cohort identified poor ECOG performance status, heavy alcohol consumption, and prior adjuvant CCRT or lack of prior RT as adverse prognostic factors. Comparison of laboratory data between patients with OS≦6 and OS > 6 also revealed unfavorable factors, including increased white blood cell count, decreased hemoglobin level, increased platelet count, increased absolute neutrophil count, decreased absolute lymphocyte count, and increased neutrophil-to-lymphocyte ratio. Using forward prediction, a three-level risk stratification prediction model was constructed using the variables of ECOG performance status, alcohol consumption, skin metastasis, modality of radiation therapy, hemoglobin level, and neutrophil-to-lymphocyte ratio. The median OS in the low-risk, intermediate-risk, and high-risk groups were 12.02 months (95% CI 10.44-13.61), 7.5 months (95% CI 7.33-8.17), and 4.01 months (95% CI 3.94-4.08), respectively, with a log-rank test p-value < 0.001. This study presents a three-level risk stratification model with strong prediction ability for OS in R/M HNSCC patients who received cetuximab-containing regimens. The results are based on real-world data and may provide valuable information for clinicians in treatment planning and future drug development. BackgroundIn recent years, the addition of cetuximab to chemotherapy has improved treatment outcomes for patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). In this study, we present the real-world survival data of R/M HNSCC patients who received cetuximab-containing regimens from thirteen medical centers in Taiwan, as well as a three-level risk stratification model for this patient population.MethodsThis study enrolled R/M HNSCC patients from thirteen medical centers in Taiwan who received cetuximab-containing regimens from January 1, 2017 to June 6, 2022. The cases were divided into a training cohort and a validation cohort based on the start of treatment. Overall survival (OS) was evaluated in both cohorts and exploratory analysis was performed to identify associated adverse clinical and laboratory factors. The results of the exploratory analysis were used to construct a three-level risk stratification prediction model for OS.ResultsA total of 1434 patients with R/M HNSCC were enrolled in this study and received cetuximab-containing regimens. The overall population had a median OS of 8.57 months (95% CI: 8.07 – 9.08). Multivariate analysis of the training cohort identified poor ECOG performance status, heavy alcohol consumption, and prior adjuvant CCRT or lack of prior RT as adverse prognostic factors. Comparison of laboratory data between patients with OS≦6 and OS > 6 also revealed unfavorable factors, including increased white blood cell count, decreased hemoglobin level, increased platelet count, increased absolute neutrophil count, decreased absolute lymphocyte count, and increased neutrophil-to-lymphocyte ratio. Using forward prediction, a three-level risk stratification prediction model was constructed using the variables of ECOG performance status, alcohol consumption, skin metastasis, modality of radiation therapy, hemoglobin level, and neutrophil-to-lymphocyte ratio. The median OS in the low-risk, intermediate-risk, and high-risk groups were 12.02 months (95% CI 10.44–13.61), 7.5 months (95% CI 7.33–8.17), and 4.01 months (95% CI 3.94–4.08), respectively, with a log-rank test p-value < 0.001.ConclusionThis study presents a three-level risk stratification model with strong prediction ability for OS in R/M HNSCC patients who received cetuximab-containing regimens. The results are based on real-world data and may provide valuable information for clinicians in treatment planning and future drug development. In recent years, the addition of cetuximab to chemotherapy has improved treatment outcomes for patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). In this study, we present the real-world survival data of R/M HNSCC patients who received cetuximab-containing regimens from thirteen medical centers in Taiwan, as well as a three-level risk stratification model for this patient population.BACKGROUNDIn recent years, the addition of cetuximab to chemotherapy has improved treatment outcomes for patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). In this study, we present the real-world survival data of R/M HNSCC patients who received cetuximab-containing regimens from thirteen medical centers in Taiwan, as well as a three-level risk stratification model for this patient population.This study enrolled R/M HNSCC patients from thirteen medical centers in Taiwan who received cetuximab-containing regimens from January 1, 2017 to June 6, 2022. The cases were divided into a training cohort and a validation cohort based on the start of treatment. Overall survival (OS) was evaluated in both cohorts and exploratory analysis was performed to identify associated adverse clinical and laboratory factors. The results of the exploratory analysis were used to construct a three-level risk stratification prediction model for OS.METHODSThis study enrolled R/M HNSCC patients from thirteen medical centers in Taiwan who received cetuximab-containing regimens from January 1, 2017 to June 6, 2022. The cases were divided into a training cohort and a validation cohort based on the start of treatment. Overall survival (OS) was evaluated in both cohorts and exploratory analysis was performed to identify associated adverse clinical and laboratory factors. The results of the exploratory analysis were used to construct a three-level risk stratification prediction model for OS.A total of 1434 patients with R/M HNSCC were enrolled in this study and received cetuximab-containing regimens. The overall population had a median OS of 8.57 months (95% CI: 8.07 - 9.08). Multivariate analysis of the training cohort identified poor ECOG performance status, heavy alcohol consumption, and prior adjuvant CCRT or lack of prior RT as adverse prognostic factors. Comparison of laboratory data between patients with OS≦6 and OS > 6 also revealed unfavorable factors, including increased white blood cell count, decreased hemoglobin level, increased platelet count, increased absolute neutrophil count, decreased absolute lymphocyte count, and increased neutrophil-to-lymphocyte ratio. Using forward prediction, a three-level risk stratification prediction model was constructed using the variables of ECOG performance status, alcohol consumption, skin metastasis, modality of radiation therapy, hemoglobin level, and neutrophil-to-lymphocyte ratio. The median OS in the low-risk, intermediate-risk, and high-risk groups were 12.02 months (95% CI 10.44-13.61), 7.5 months (95% CI 7.33-8.17), and 4.01 months (95% CI 3.94-4.08), respectively, with a log-rank test p-value < 0.001.RESULTSA total of 1434 patients with R/M HNSCC were enrolled in this study and received cetuximab-containing regimens. The overall population had a median OS of 8.57 months (95% CI: 8.07 - 9.08). Multivariate analysis of the training cohort identified poor ECOG performance status, heavy alcohol consumption, and prior adjuvant CCRT or lack of prior RT as adverse prognostic factors. Comparison of laboratory data between patients with OS≦6 and OS > 6 also revealed unfavorable factors, including increased white blood cell count, decreased hemoglobin level, increased platelet count, increased absolute neutrophil count, decreased absolute lymphocyte count, and increased neutrophil-to-lymphocyte ratio. Using forward prediction, a three-level risk stratification prediction model was constructed using the variables of ECOG performance status, alcohol consumption, skin metastasis, modality of radiation therapy, hemoglobin level, and neutrophil-to-lymphocyte ratio. The median OS in the low-risk, intermediate-risk, and high-risk groups were 12.02 months (95% CI 10.44-13.61), 7.5 months (95% CI 7.33-8.17), and 4.01 months (95% CI 3.94-4.08), respectively, with a log-rank test p-value < 0.001.This study presents a three-level risk stratification model with strong prediction ability for OS in R/M HNSCC patients who received cetuximab-containing regimens. The results are based on real-world data and may provide valuable information for clinicians in treatment planning and future drug development.CONCLUSIONThis study presents a three-level risk stratification model with strong prediction ability for OS in R/M HNSCC patients who received cetuximab-containing regimens. The results are based on real-world data and may provide valuable information for clinicians in treatment planning and future drug development. |
| ArticleNumber | 1227 |
| Audience | Academic |
| Author | Yen, Chia-Jui Wang, Chen-Chi Lien, Ming-Yu Huang, Tai-Lin Chien, Chih-Yen Hsieh, Jason Chia-Hsun Yiu, Ching-Yi Chen, Jo-Pai Chang, Yi-Fang Wang, Hui-Ching Lu, Wei-Chen Wang, Hung-Ming Hua, Chun-Hung Huang, Huai-Cheng Chu, Pen-Yuan Wu, Shang-Yin Lin, Jin-Ching Liu, Yi-Chun Chen, Tien-Hua Lin, Chien-Liang Yang, Muh-Hwa Lou, Pei-Jen Hsieh, Meng-Che Lu, Hsueh-Ju |
| Author_xml | – sequence: 1 givenname: Muh-Hwa surname: Yang fullname: Yang, Muh-Hwa – sequence: 2 givenname: Tien-Hua surname: Chen fullname: Chen, Tien-Hua – sequence: 3 givenname: Hung-Ming surname: Wang fullname: Wang, Hung-Ming – sequence: 4 givenname: Jason Chia-Hsun surname: Hsieh fullname: Hsieh, Jason Chia-Hsun – sequence: 5 givenname: Huai-Cheng surname: Huang fullname: Huang, Huai-Cheng – sequence: 6 givenname: Meng-Che surname: Hsieh fullname: Hsieh, Meng-Che – sequence: 7 givenname: Chia-Jui surname: Yen fullname: Yen, Chia-Jui – sequence: 8 givenname: Shang-Yin surname: Wu fullname: Wu, Shang-Yin – sequence: 9 givenname: Chun-Hung surname: Hua fullname: Hua, Chun-Hung – sequence: 10 givenname: Ming-Yu surname: Lien fullname: Lien, Ming-Yu – sequence: 11 givenname: Yi-Fang surname: Chang fullname: Chang, Yi-Fang – sequence: 12 givenname: Hui-Ching surname: Wang fullname: Wang, Hui-Ching – sequence: 13 givenname: Chih-Yen surname: Chien fullname: Chien, Chih-Yen – sequence: 14 givenname: Tai-Lin surname: Huang fullname: Huang, Tai-Lin – sequence: 15 givenname: Hsueh-Ju surname: Lu fullname: Lu, Hsueh-Ju – sequence: 16 givenname: Jin-Ching surname: Lin fullname: Lin, Jin-Ching – sequence: 17 givenname: Chen-Chi surname: Wang fullname: Wang, Chen-Chi – sequence: 18 givenname: Yi-Chun surname: Liu fullname: Liu, Yi-Chun – sequence: 19 givenname: Jo-Pai surname: Chen fullname: Chen, Jo-Pai – sequence: 20 givenname: Wei-Chen surname: Lu fullname: Lu, Wei-Chen – sequence: 21 givenname: Ching-Yi surname: Yiu fullname: Yiu, Ching-Yi – sequence: 22 givenname: Chien-Liang surname: Lin fullname: Lin, Chien-Liang – sequence: 23 givenname: Pei-Jen surname: Lou fullname: Lou, Pei-Jen – sequence: 24 givenname: Pen-Yuan surname: Chu fullname: Chu, Pen-Yuan |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39369189$$D View this record in MEDLINE/PubMed |
| BookMark | eNptk9tuFSEUhiemxh70BbwwJCZGL6bCMLCZK9M0HnbSROPhmjALZjbtDLTAaH0WX1Zm71r3GEMCBL71Az9rHRcHzjtTFE8JPiVE8NeRVEKwEld1Saq6yrMHxRGpV6Ssarw62JsfFscxXmJMVgKLR8UhbShviGiOil-fgu-dj8kC6hQkHyJSTqNg41UZU1DJdhZy7x0avTYD8h0KBqYQjEvIBzSapGJSs8DGKL2NdgauULyZ1OiniMAMAwIVwDo_KpSCUclo9MOmTd5L060dVYvAu6Sss67P-r0djXtcPOzUEM2Tu_Gk-Pbu7dfzD-XFx_fr87OLEpjAqRRNBxi0EHRFOwyCmJVuMKOKirYRtaaEEc47YVaYaqEpA6gE54ANFqoiFT0p1jtd7dWlvA75OuGn9MrK7YIPvVQhv28wEnDbMmCcAWF1AyCaGvMOVMO7Vmkustabndb11I5GQzYpqGEhutxxdiN7_10SUrOqETwrvLxTCP5mMjHJ0cbZQuVMdlNSQigVmDOS0ef_oJd-Ci57NVMsJwWv6r9Ur_ILrOt8PhhmUXkmCKlYtqfJ1Ol_qNy0GW3-G9PZvL4IeLUImP_P3KZeTTHK9ZfPS_bFHpvTZEib6IdpTqu4BJ_t23fv25-EzUC1AyD4GIPp7hGC5VwVclcVMleF3FaFxPQ3JoP_Dw |
| Cites_doi | 10.3390/cancers13020338 10.1177/0194599818764651 10.1155/2020/1408793 10.1186/s12885-022-10440-7 10.1056/NEJMoa032641 10.1007/s11864-011-0176-y 10.1634/theoncologist.5-suppl_2-13 10.3322/caac.21660 10.1007/s11864-005-0011-4 10.1016/j.ejca.2019.03.022 10.3322/caac.21654 10.1056/NEJMoa0802656 10.1002/hed.24986 10.1002/hed.25636 10.1002/cncr.20640 10.1002/hed.25366 10.1200/JCO.2006.06.7447 10.1016/j.neo.2022.100855 10.1016/S1470-2045(20)30755-5 10.1002/hed.24576 10.14639/0392-100X-1246 |
| ContentType | Journal Article |
| Copyright | 2024. The Author(s). COPYRIGHT 2024 BioMed Central Ltd. 2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2024 2024 |
| Copyright_xml | – notice: 2024. The Author(s). – notice: COPYRIGHT 2024 BioMed Central Ltd. – notice: 2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2024 2024 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM ISR 3V. 7TO 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI 7X8 5PM DOA |
| DOI | 10.1186/s12885-024-12425-0 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Science ProQuest Central (Corporate) Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic ProQuest Publicly Available Content ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE Publicly Available Content Database MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1471-2407 |
| EndPage | 11 |
| ExternalDocumentID | oai_doaj_org_article_c0bb5c565c1549cc89406fca96fbad68 PMC11452986 A811255169 39369189 10_1186_s12885_024_12425_0 |
| Genre | Multicenter Study Journal Article |
| GeographicLocations | Taiwan |
| GeographicLocations_xml | – name: Taiwan |
| GroupedDBID | --- 0R~ 23N 2WC 53G 5VS 6J9 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL AAYXX ABDBF ABUWG ACGFO ACGFS ACIHN ACMJI ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR IHW INH INR ISR ITC KQ8 LGEZI LOTEE M1P M48 M~E NADUK NXXTH O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SBL SOJ SV3 TR2 TUS U2A UKHRP W2D WOQ WOW XSB CGR CUY CVF ECM EIF NPM PJZUB PPXIY PMFND 3V. 7TO 7XB 8FK AZQEC DWQXO H94 K9. PKEHL PQEST PQUKI 7X8 5PM PUEGO |
| ID | FETCH-LOGICAL-c580t-89fc0cd88373f0c81e7d9053a38b984d315166f8e703d8d35cc2866c0e08a2123 |
| IEDL.DBID | M48 |
| ISSN | 1471-2407 |
| IngestDate | Wed Aug 27 01:28:48 EDT 2025 Thu Aug 21 18:36:07 EDT 2025 Fri Jul 11 07:43:55 EDT 2025 Fri Jul 25 22:43:20 EDT 2025 Tue Jun 17 22:04:01 EDT 2025 Tue Jun 10 20:58:58 EDT 2025 Fri Jun 27 05:27:49 EDT 2025 Thu May 22 21:26:51 EDT 2025 Mon Jul 21 05:49:24 EDT 2025 Tue Jul 01 04:29:48 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Prognostic factor Head and neck squamous cell carcinoma Cetuximab Risk-stratification model |
| Language | English |
| License | 2024. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c580t-89fc0cd88373f0c81e7d9053a38b984d315166f8e703d8d35cc2866c0e08a2123 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s12885-024-12425-0 |
| PMID | 39369189 |
| PQID | 3115124624 |
| PQPubID | 44074 |
| PageCount | 11 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_c0bb5c565c1549cc89406fca96fbad68 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11452986 proquest_miscellaneous_3113380651 proquest_journals_3115124624 gale_infotracmisc_A811255169 gale_infotracacademiconefile_A811255169 gale_incontextgauss_ISR_A811255169 gale_healthsolutions_A811255169 pubmed_primary_39369189 crossref_primary_10_1186_s12885_024_12425_0 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2024-10-05 |
| PublicationDateYYYYMMDD | 2024-10-05 |
| PublicationDate_xml | – month: 10 year: 2024 text: 2024-10-05 day: 05 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | BMC cancer |
| PublicationTitleAlternate | BMC Cancer |
| PublicationYear | 2024 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | Y Takenaka (12425_CR16) 2018; 40 S Kano (12425_CR14) 2017; 39 K Hu (12425_CR18) 2005; 6 A Argiris (12425_CR12) 2004; 101 J Bernier (12425_CR4) 2004; 350 KA Price (12425_CR6) 2012; 13 JB Vermorken (12425_CR7) 2008; 359 H Sung (12425_CR1) 2021; 71 YC Huang (12425_CR2) 2020; 2020 TL Lee (12425_CR20) 2023; 35 YK So (12425_CR15) 2018; 159 RL Siegel (12425_CR3) 2021; 71 J Guigay (12425_CR8) 2021; 22 JB Vermorken (12425_CR9) 2007; 25 R Depenni (12425_CR13) 2019; 115 G Cadoni (12425_CR11) 2017; 37 P Kumar (12425_CR19) 2000; 5 Y Takenaka (12425_CR17) 2018; 40 A Mirabile (12425_CR21) 2019; 41 TH Chen (12425_CR10) 2022; 22 12425_CR5 |
| References_xml | – ident: 12425_CR5 doi: 10.3390/cancers13020338 – volume: 159 start-page: 303 issue: 2 year: 2018 ident: 12425_CR15 publication-title: Otolaryngol Head Neck Surg doi: 10.1177/0194599818764651 – volume: 2020 start-page: 1408793 year: 2020 ident: 12425_CR2 publication-title: J Oncol doi: 10.1155/2020/1408793 – volume: 22 start-page: 1336 issue: 1 year: 2022 ident: 12425_CR10 publication-title: BMC Cancer doi: 10.1186/s12885-022-10440-7 – volume: 350 start-page: 1945 issue: 19 year: 2004 ident: 12425_CR4 publication-title: N Engl J Med doi: 10.1056/NEJMoa032641 – volume: 13 start-page: 35 issue: 1 year: 2012 ident: 12425_CR6 publication-title: Curr Treat Options Oncol doi: 10.1007/s11864-011-0176-y – volume: 5 start-page: 13 issue: 90002 year: 2000 ident: 12425_CR19 publication-title: Oncologist doi: 10.1634/theoncologist.5-suppl_2-13 – volume: 71 start-page: 209 issue: 3 year: 2021 ident: 12425_CR1 publication-title: CA Cancer J Clin doi: 10.3322/caac.21660 – volume: 6 start-page: 31 issue: 1 year: 2005 ident: 12425_CR18 publication-title: Curr Treat Options Oncol doi: 10.1007/s11864-005-0011-4 – volume: 115 start-page: 4 year: 2019 ident: 12425_CR13 publication-title: Eur J Cancer doi: 10.1016/j.ejca.2019.03.022 – volume: 71 start-page: 7 issue: 1 year: 2021 ident: 12425_CR3 publication-title: CA Cancer J Clin doi: 10.3322/caac.21654 – volume: 359 start-page: 1116 issue: 11 year: 2008 ident: 12425_CR7 publication-title: N Engl J Med doi: 10.1056/NEJMoa0802656 – volume: 40 start-page: 647 issue: 3 year: 2018 ident: 12425_CR16 publication-title: Head Neck doi: 10.1002/hed.24986 – volume: 41 start-page: 1895 issue: 6 year: 2019 ident: 12425_CR21 publication-title: Head Neck doi: 10.1002/hed.25636 – volume: 101 start-page: 2222 issue: 10 year: 2004 ident: 12425_CR12 publication-title: Cancer doi: 10.1002/cncr.20640 – volume: 40 start-page: 2714 issue: 12 year: 2018 ident: 12425_CR17 publication-title: Head Neck doi: 10.1002/hed.25366 – volume: 25 start-page: 2171 issue: 16 year: 2007 ident: 12425_CR9 publication-title: J Clin Oncol doi: 10.1200/JCO.2006.06.7447 – volume: 35 start-page: 100855 year: 2023 ident: 12425_CR20 publication-title: Neoplasia doi: 10.1016/j.neo.2022.100855 – volume: 22 start-page: 463 issue: 4 year: 2021 ident: 12425_CR8 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(20)30755-5 – volume: 39 start-page: 247 issue: 2 year: 2017 ident: 12425_CR14 publication-title: Head Neck doi: 10.1002/hed.24576 – volume: 37 start-page: 458 issue: 6 year: 2017 ident: 12425_CR11 publication-title: Acta Otorhinolaryngol Ital doi: 10.14639/0392-100X-1246 |
| SSID | ssj0017808 |
| Score | 2.4300616 |
| Snippet | In recent years, the addition of cetuximab to chemotherapy has improved treatment outcomes for patients with recurrent/metastatic head and neck squamous cell... Background In recent years, the addition of cetuximab to chemotherapy has improved treatment outcomes for patients with recurrent/metastatic head and neck... BackgroundIn recent years, the addition of cetuximab to chemotherapy has improved treatment outcomes for patients with recurrent/metastatic head and neck... Abstract Background In recent years, the addition of cetuximab to chemotherapy has improved treatment outcomes for patients with recurrent/metastatic head and... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | 1227 |
| SubjectTerms | Adult Aged Alcohol Alcohol use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biochemistry Blood cell count Blood levels Cancer Cancer therapies Care and treatment Cell number Cetuximab Cetuximab - administration & dosage Cetuximab - therapeutic use Chemotherapy Clinical outcomes Drug development Female Head & neck cancer Head and neck cancer Head and neck carcinoma Head and Neck Neoplasms - drug therapy Head and Neck Neoplasms - mortality Head and Neck Neoplasms - pathology Head and neck squamous cell carcinoma Health aspects Hematology Hemoglobin Human papillomavirus Humans Induction therapy Leukocytes (neutrophilic) Lymphocytes Male Medical centers Medical prognosis Medical research Medicine, Experimental Metastases Metastasis Middle Aged Monoclonal antibodies Multivariate analysis Neoplasm Recurrence, Local Neutrophils Patients Population studies Prediction models Prevention Prognosis Prognostic factor Radiation therapy Radiotherapy Relapse Response rates Retrospective Studies Risk Assessment - methods Risk Factors Risk groups Risk-stratification model Squamous cell carcinoma Squamous Cell Carcinoma of Head and Neck - drug therapy Squamous Cell Carcinoma of Head and Neck - mortality Squamous Cell Carcinoma of Head and Neck - pathology Statistical significance Surgery Survival analysis Taiwan - epidemiology Targeted cancer therapy Variables |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9QwDI7QHhAXxJvCAgEhcUDV9pk6xwWxWpAWIWClvUWpk7ArNC1MOxL_hT-LnXZGU3HgwnXsVtP4lTj2ZyFeatcq0DakNmBIK63yFLzVaa08etU4W8UpEWcf1el59eGivtgb9cU1YRM88LRwR5i1bY207UAGE0METSEooNUqtNap2OZLMW97mJrvDxrIYNsiA-poIC8M3InMGH2kpWm2CEMRrf9vn7wXlJYFk3sR6OSWuDlvHeXx9Jdvi2u-uyOun82X43fF70_rnsvmiCznMTrSdk5y9Xg6weOGOUMn4wAc2Qe55nw7IzTJfi1XfrTcYUQvIB_t4tOdx-9y-LmxnCOQnOeXyPOHun5lZSxT905yNpdo4-bX1cq2kuvfp8kTkgc_rHx3T5yfvPv69jSdZy-kWEM2pqADZuiAzq9lyBBy3zhNBmtLaDVUrqSdglIBPHkMB66sEQtQCjOfgeVweF8cdH3nHwpZubbBRjd1kYUqhNISkyMBNi2GtshDIl5vRWF-TBAbJh5NQJlJcIYEZ6LgTJaINyytHSfDY8cfSGnMrDTmX0qTiGcsazP1mu6M3BwDbT_j1WEiXkQOhsjouAbnm90Mg3n_5fOC6dXMFHqSItq5pYG-m1G1FpyHC06yYVySt0pnZh8yGMZBoo9WRZWI5zsyP8l1cZ0nqTNPWfLdeJ6IB5OO7lam5FmNOdDLYaG9i6VbUrqry4gwTofkutCgHv2PxX4sbhTR8rjq4lAcjOuNf0I7ubF9Go32D8nmSjw priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9RAEF-0gvgifhutuorgg4TmczN5kiqWKlRELfRt2czutkUuaS934P_iP-vMZu9sEHy9mSSXzNfu7MxvhHjd2k5Ba3xqPPq0alWegjNtWiuHTjXWVGFKxNEXdXhcfT6pT2LCbYxllRufGBy1HZBz5HuMCkOxSBXVu4vLlKdG8elqHKFxXdxg6DLW6uZku-HKG8hg0ygDam8kXwzcj8xIfaSraTYLRgGz_1_PfCU0zcsmr8ShgzvidlxAyv1J4nfFNdffEzeP4hH5ffH763Lg4jkiyzhMR5reSq4hTyeQXB_zdDKMwZGDl0vOujNOkxyWcuFWhvuM6AbkqW24unf4U46Xa8OZAsnZfok8hagfFkaGYnVnJed0ibZa_zpfmE5yFfw0f0Ly-IeF6x-I44OPPz4cpnECQ4o1ZKsUWo8ZWqBdbOkzhNw1tiWzNSV0LVS2JJko5cGR37BgyxqxAKUwcxkYDooPxU4_9O6xkJXtGmzapi4yX3lfGmKyaNqmQ98VuU_E240o9MUEtKHDBgWUngSnSXA6CE5niXjP0tpyMkh2-GFYnupocxqzrquRVqzIOHSI0NLqxdMzle-MVZCIFyxrPXWcbk1d7wMtQsMBYiJeBQ4Gyui5EufUrMdRf_r-bcb0JjL5gaSIJjY20HszttaMc3fGSZaMc_JG6XT0JKP-q_eJeLkl85VcHdc7kjrzlCWfkOeJeDTp6PbLlDyxMQe6Ocy0d_bp5pT-_CzgjNNWuS5aUE_-_7-eiltFsCmuqtgVO6vl2j2jldqqex7M8Q9yRkC- priority: 102 providerName: ProQuest |
| Title | Prognostic factors and risk-stratification model of recurrent or metastatic head and neck squamous cell carcinoma treated with cetuximab containing regimen |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/39369189 https://www.proquest.com/docview/3115124624 https://www.proquest.com/docview/3113380651 https://pubmed.ncbi.nlm.nih.gov/PMC11452986 https://doaj.org/article/c0bb5c565c1549cc89406fca96fbad68 |
| Volume | 24 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LbxMxELZKKyEuiDcLJRiExAEt3acfB4Qa1KogpaoCkSoultePUkF26SaRym_hzzLj3YSuqLjkEM86WY9nPPaMv4-QV9JWTEjtY-2NjwvJ0lg4LeOSOeMYt7oILBGTY3Y0Kz6dlqdbZE131A_g4tqtHfJJzdofby8vfr0Hg38XDF6wvQX4WIH3jBGBD-ZgDFv4HViZODIaTIq_WQUuAkNdCg4Zswp8fYnm2j4GC1XA8__Xa19ZtoYllVfWqMM75HYfXNL9bjbcJVuuvkduTvr0-X3y-6RtsLAOmmlPtEN1bSnWl8cdgK7vz_BooMihjactnsgjhhNtWjp3S413kKAD8OI2PF07850uLlYaTxEoZgKoQYaiuplrGgrZnaV43gtty9Xl-VxXFCvkO24KitQQc1c_ILPDgy8fjuKenSE2pUiWsZDeJMYK2OHmPjEiddxKMGmdi0qKwuYQSzDmhQOfYoXNS2MywZhJXCI0LpgPyXbd1O4xoYWtuOGSl1niC-9zDULWaMkr46ss9RF5s1aF-tmBcKiweRFMdYpToDgVFKeSiIxRWxtJBNAOXzTtmertUZmkqkoD0axBjDpjhITIxsNvMl9py0REnqOuVXcbdeMG1L6AADUkFyPyMkggiEaNVTpnerVYqI-fpwOh172Qb0CLRveXHuC9EXdrILk7kAQrN8Pm9aRTayNRiJQEL82yIiIvNs34JFbO1Q60jjJ5jtnzNCKPujm6GZkc2RxTAZ2LwewdDN2wpT7_FjDIYRtdZlKwJ___20_JrSzYFFZc7JLtZbtyzyCKW1YjcoOf8hHZGR8cn0xH4SxkFMwVPqfjr38AeiNKEA |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Zb9QwELZKkYAXxE2gUINAPKCoOZ3JA0LlqLq0WyFopX0zjo9SoU3aza6A38J_4Dcy42SXRki89TWeOMdcHntmPsaelaYSUCoXKqddmJUiDsGqMsyF1VYURmUeJWJ8IHaPsg-TfLLGfi9rYSitcmkTvaE2jaY98i3qCoO-SCTZ69OzkFCj6HR1CaHRicWe_fkdQ7b21egd8vd5kuy8P3y7G_aoAqHOIZqHUDodaQMYmaUu0hDbwpQoiiqFqoTMpPgcIRxY1AUDJs21TkAIHdkIFBl6nPcSu4yON6Jgr5isAry4gAiWhTkgtlq0_UD1z9QZEHUjjAbOz2ME_OsJzrnCYZrmOb-3c4Nd7xesfLuTsJtszda32JVxfyR_m_36OGsoWQ-HeQ_ew1VtOOWsh11TXtfvC3IPu8Mbx2e0y099oXgz41M7V1TXhBOgZzD-7trqb7w9WyjameB0usA1oR7VzVRxnxxvDac9ZBybL36cTFXFKeu-w7vgBDcxtfUddnQhvLnL1uumtvcZz0xV6KIs8iRymXOpQiKjVVlU2lVJ7AL2cskKedo19pA-IAIhO8ZJZJz0jJNRwN4Qt1aU1JTbX2hmx7LXcamjqso1rpA19b3TGkpcLTl8pnCVMgICtkm8ll2F68q0yG3ARa8_sAzYU09BjTlqyvw5Vou2laPPnwZEL3oi1yAXteoLKfC7qZfXgHJjQImWQw-Hl0Ine8vVyr96FrAnq2G6k7LxaotcJ5o0pRP5OGD3Ohld_ZmUECJjwMlhIL2DXzccqU---r7mGJrnSQniwf_fa5Nd3T0c78v90cHeQ3Yt8fpFGR0bbH0-W9hHuEqcV4-9anL25aJtwR8bMnv_ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prognostic+factors+and+risk-stratification+model+of+recurrent+or+metastatic+head+and+neck+squamous+cell+carcinoma+treated+with+cetuximab+containing+regimen&rft.jtitle=BMC+cancer&rft.au=Yang%2C+Muh-Hwa&rft.au=Chen%2C+Tien-Hua&rft.au=Wang%2C+Hung-Ming&rft.au=Hsieh%2C+Jason+Chia-Hsun&rft.date=2024-10-05&rft.pub=BioMed+Central+Ltd&rft.issn=1471-2407&rft.eissn=1471-2407&rft.volume=24&rft.issue=1&rft_id=info:doi/10.1186%2Fs12885-024-12425-0&rft.externalDocID=A811255169 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2407&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2407&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2407&client=summon |